IP Library Granted Patent US 7,319,024
Granted Patent B1
US 7,319,024 · App. 11/045,439 · Granted Jan 15, 2008

C. elegans p21-activated kinase (PAK) gene and associated loss-of-function phenotypes that facilitate screening for small molecule modulators of PAK activity in the nematode, caenorhabditis elegans

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,319,024
App. No.
11/045,439
Granted
Jan 15, 2008
Kind
B1
Abstract

The invention refers to a novel C. elegans p21-activated kinase gene, the pak-3 gene, and associated loss-of-function phenotypes. These phenotypes can be used to elucidate PAK signaling pathways in C. elegans and to screen compounds that modulate PAK signaling.

Claims (10)

1. An isolated polynucleotide comprising a DNA sequence selected from one of the following groups:

a] a DNA sequence of SEQ ID NO. 1; or

b] a DNA sequence which is complementary to SEQ ID NO. 1; or

c] a DNA sequence which is degenerate as a result of the genetic code to the DNA sequence of SEQ ID NO. 1.

2. An isolated polynucleotide comprising a polynucleotide sequence of SEQ ID NO. 1.

3. A recombinant vector sequence comprising SEQ ID NO. 1.

4. An isolated host cell comprising the recombinant vector of claim 3 .

5. The isolated host cell of claim 4 which is a cell of E. coli or of Saccharomyces cerevisiae.

6. A method of manufacturing an RNA molecule wherein the recombinant vector of claim 3 is transformed into a bacterial strain, the RNA is transcribed from the vector and the transcribed RNA is isolated and/or purified.

7. An RNA molecule obtained by the method of claim 6 .